drugset / Trial / NCT02970682
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 study to demonstrate the safety and efficacy of SFX-01 when used in combination with aromatase inhibitors (AIs), tamoxifen and fulvestrant. Patients will be enrolled into one of three study arms (SFX-01 in combination with AI, tamoxifen or fulvestrant) based on their current therapy.
Timeline
- Start
- 2016-10
- Primary completion
- 2019-01
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sulforaphane | Small molecule | 300 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Background | Tamoxifen | Small molecule | — | — |